A multicenter, open label phase I/ii study of carfilzomib, pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma (mm) patients

Study map

Overview / Summary

Study details

Patient eligibility criteria

Patients with MM, who received 1-3 prior lines of treatments. Subjects must be relapsed/refractory to Lenalidomide. Both relapsed and/or refractory to Bortezomib and naive to Bortezomib patients can be enrolled.